RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

@article{Sordillo2003RANKFcAT,
  title={RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.},
  author={Emilia Mia Sordillo and Roger Niles Pearse},
  journal={Cancer},
  year={2003},
  volume={97 3 Suppl},
  pages={
          802-12
        }
}
BACKGROUND Severe bone destruction due to inappropriate osteoclastogenesis is a prominent feature of multiple myeloma (MM). MM increases bone loss by disrupting the checks that normally control signaling by receptor activator of nuclear factor kappaB ligand (RANK-L, also called TRANCE [tumor necrosis factor-related, activation-induced cytokine], osteoprotegerin ligand [OPG-L], osteoclast differentiation factor [ODF], and tumor necrosis factor superfamily member 11 [TNFSF11]), a TNF-family… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 44 CITATIONS

Hydrodynamics-based transfection of plasmid encoding receptor activator for nuclear factor kappa B-Fc protects against hepatic ischemia/reperfusion injury in mice.

  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2010
VIEW 9 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma

  • Clinical Reviews in Bone and Mineral Metabolism
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Identification of a prognostic 5-Gene expression signature for gastric cancer

  • Journal of Cancer Research and Clinical Oncology
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

The use of animal models in multiple myeloma.

  • Morphologie : bulletin de l'Association des anatomistes
  • 2015